Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

157.61USD
20 Apr 2018
Change (% chg)

$-1.94 (-1.22%)
Prev Close
$159.55
Open
$159.61
Day's High
$159.84
Day's Low
$157.50
Volume
329,272
Avg. Vol
617,418
52-wk High
$178.17
52-wk Low
$113.66

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $39,103.64
Shares Outstanding(Mil.): 252.12
Dividend: --
Yield (%): --

Financials

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

18 Apr 2018

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Vertex Pharmaceuticals CEO Leiden's 2017 Compensation Was $17.2 Mln

* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:

07 Apr 2018

BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals

* PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES

04 Apr 2018

BRIEF-Vertex Appoints Reshma Kewalramani As Chief Medical Officer

* VERTEX APPOINTS RESHMA KEWALRAMANI, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

26 Feb 2018

BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis

* VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

22 Feb 2018

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

14 Feb 2018

UPDATE 1-U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

13 Feb 2018

U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

13 Feb 2018

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

13 Feb 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.66 -0.89
Pfizer Inc. (PFE.N) $36.63 +0.10
Novartis AG (NOVN.S) CHF76.08 -1.20
Merck & Co., Inc. (MRK.N) $58.83 +0.19
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Sanofi SA (SASY.PA) €65.28 -0.32
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60
AbbVie Inc (ABBV.N) $92.60 -0.41
Bristol-Myers Squibb Co (BMY.N) $51.17 -0.44

Earnings vs. Estimates